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Background: Constitutive activation of STAT3 is one of the major oncogenic pathways involved in the
development of various types of malignancies including colorectal cancer (CRC); and thus becomes a promising
therapeutic target. Spica Prunellae has long been used as an important component in many traditional Chinese
medicine formulas to clinically treat CRC. Previously, we found that Spica Prunellae inhibits CRC cell growth through
mitochondrion-mediated apoptosis. Furthermore, we demonstrated its anti-angiogenic activities in vivo and in vitro.
To further elucidate the precise mechanism of the potential tumoricidal activity of Spica Prunellae, using a CRC
mouse xenograft model, in this study we evaluated its therapeutic efficacy against CRC and investigated the
underlying molecular mechanisms.
Methods: CRC mouse xenograft model was generated by subcutaneous injection of human colon carcinoma
HT-29 cells into nude mice. Animals were given intra-gastric administration with 6 g/kg of the ethanol extract of
Spica Prunellae (EESP) daily, 5 days a week for 16 days. Body weight and tumor growth were measured every two
days. Tumor growth in vivo was determined by measuring the tumor volume and weight. HT-29 cell viability was
examined by MTT assay. Cell apoptosis and proliferation in tumors from CRC xenograft mice was evaluated via
immunohistochemical staining (IHS) for TUNEL and PCNA, and the intratumoral microvessel density (MVD) was
examined by using IHS for the endothelial cell-specific marker CD31. The activation of STAT3 was evaluated by
determining its phosphorylation level using IHS. The mRNA and protein expression of Bcl-2, Bax, Cyclin D1, VEGF-A
and VEGFR2 was measured by RT-PCR and IHS, respectively.
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Results: EESP treatment reduced tumor volume and tumor weight but had no effect on body weight change in
CRC mice; decreased HT-29 cell viability in a dose-dependent manner, suggesting that EESP displays therapeutic
efficacy against colon cancer growth in vivo and in vitro, without apparent toxicity. In addition, EESP significantly
inhibited the phosphorylation of STAT3 in tumor tissues, indicating its suppressive action on the activation of STAT3
signaling. Consequently, the inhibitory effect of EESP on STAT3 activation resulted in an increase in the
pro-apoptotic Bax/Bcl-2 ratio, decrease in the expression of the pro-proliferative Cyclin D1 and CDK4, as well as
down-regulation of pro-angiogenic VEGF-A and VEGFR-2 expression. Finally, these molecular effects led to the
induction of apoptosis, the inhibition of cell proliferation and tumor angiogenesis.
Conclusions: Spica Prunellae possesses a broad range of anti-cancer activities due to its ability to affect STAT3
pathway, suggesting that Spica Prunellae could be a novel potent therapeutic agent for the treatment of CRC.
Keywords: Spica prunellae, Colorectal cancer, Herbal medicine, STAT3 pathway, Apoptosis, Proliferation,
AngiogenesisBackground
Colorectal carcinoma (CRC) is a serious public health
problem, with over one million new cases worldwide
each year [1]. In Western societies CRC represents the
second most common cause of cancer-related death [2].
The pathogenesis of CRC is complex and heterogeneous,
with the involvement of multiple cellular signaling trans-
duction cascades including signal transducer and acti-
vator of transcription 3 (STAT3). As one of the most
important transcription factors, STAT3 is involved in
the control of many fundamental biological processes,
such as cell proliferation, apoptosis and angiogenesis
[3-8]. STAT3 can be activated by many cytokines and
growth factors, such as IL-6 and EGF [9,10], which is
mediated by phosphorylation of STAT3 at tyrosine 705
after the binding of IL-6 or EGF to the specific cell sur-
face receptors [11]. Phosphorylated STAT3 proteins in
the cytoplasm dimerize and translocate to the nucleus
where they regulate the expression of genes containing
STAT3-binding sites in their promoters [12]. STAT3 ac-
tivation is rapid and transient in normal cells; however,
in cancer cells STAT3 is constitutively activated,
resulting in imbalance between cell proliferation and
apoptosis, and uncontrolled tumor angiogenesis. Consti-
tutive activation of STAT3 has been found in numerous
types of human cancer including CRC and commonly
suggests poor prognosis [13-23].Therefore, suppression
of STAT3 pathway has been a major therapeutic target
for treatment of cancer.
Despite recent advances in CRC chemotherapy,
5-fluorouracil (5-FU)-based regimens continue to be
the international standard chemotherapy for patients
with invasive and metastatic advanced CRC [24]. How-
ever, due to drug resistance and the unacceptable level
of toxicity to normal cells, systemic chemotherapy using
5-FU-based regimens produces objective response rates
of less than 40% [25,26]. These problems highlight the
urgent need for the development of novel cancerchemotherapies. Natural products, such as traditional
Chinese herbal medicines, have received attention as
they have relatively few side-effects and have long been
used clinically as significant alternative remedies for a
variety of diseases [27-29]. Spica Prunellae, the fruit-
spikes of the perennial plant Prunella vulgaris L., is a
medicinal herb widely distributed in northeast Asia. As
a well-known Chinese folk medicinal herb with proper-
ties of heat-clearing and detoxification, Spica Prunellae
is used to treat poor vision, blood stasis and edema,
acute conjunctivitis, lymphatic tuberculosis and scrof-
ula, acute mastitis and mammary gland hyperplasia,
thyromegaly, and hypertention [30]. Moreover, Spica
Prunellae is believed to possess anti-cancer activity
since in traditional Chinese medicine (TCM) system,
accumulation of heat and toxic dampness is a major
causative factor for tumorigenesis. Indeed, Spica
Prunellae has long been used as an important compo-
nent in several TCM formulas for the clinical treatment
of several kinds of cancer including CRC [31,32]. Al-
though we previously reported that the extract of Spica
Prunellae promotes the apoptosis of human colon car-
cinoma cells and displays anti-angiogenic activity
in vitro [33,34], the mode of its anti-cancer action re-
mains largely unknown. To further elucidate the mech-
anism of the tumorcidal activity of Spica Prunellae,
using a CRC mouse xenograft model in the present
study we evaluated the therapeutic efficacy of the etha-
nol extract of Spica Prunellae (EESP) against tumor




Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine
serum (FBS), penicillin-streptomycin, trypsin-EDTA, Trizol
reagent were purchased from Invitrogen (Carlsbad, NM,
USA). SuperScript II reverse transcriptase was provided by
Figure 1 HPLC analysis of EESP. The mobile phase consisted of
methanol:0.1% phosphoric acid solution (50:50) at a flow rate of 1
ml/min. (A) EESP; (B) Rosmarinic acid.
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CyclinD1, CDK4, VEGF-A, VEGFR antibodies, horseradish
peroxidase (HRP)-conjugated secondary anti-bodies were
obtained from Cell Signaling (Beverly, MA, USA). TUNEL
assay kit was purchased from R&D Systems (Minneapolis,
MN, USA). All the other chemicals used, unless otherwise
stated, were obtained from Sigma Chemicals (St. Louis,
MO, USA).
Preparation of ethanol extract from spica prunellae
Authentic plant material was purchased from Guo Yi Tang
Chinese Herbal medicine store (Fujian, China). The ori-
ginal herb was collected in Hunan Province, China, and
was identified as Spica Prunellae by Professor Chengzi
Yang at Department of Pharmacology, Fujian University of
Traditional Chinese Medicine (FJTCM), China. Voucher
specimen was deposited at the Herbarium of the Depart-
ment of Pharmacology, FJTCM. 500 g of Spica Prunellae
were extracted with 5000 ml of 85% ethanol using a
refluxing method and filtered. The ethanol solvent was
evaporated on a rotary evaporator (Shanghai Yarong,
Model RE-2000, China) and concentrated to a relative
density of 1.05. A dried powder of ethanol extract of Spica
Prunellae (named EESP) was obtained by spray desicca-
tion using a spray dryer (Buchi, Model B-290, Swiss). For
animal experiments, the powder of EESP was dissolved in
saline to a working concentration of 600 mg/ml. The stock
solution of EESP in cell-based experiments was prepared
by dissolving EESP powder in DMSO to a stock concen-
tration of 200 mg/ml and the working concentrations
were made by diluting the stock solution in the cell cul-
ture medium. The final concentration of DMSO in the
medium for all cell experiments was < 0.5%.
HPLC analysis
EESP was analyzed on an Agilent 1200 HPLC system
(Agilent, Santa Clara, CA, USA) using a C-18 column
(4.6 mm× 150 mm, 5 μm). Absorbance was measured at
355 nm (Figure 1). The mobile phase consisted of metha-
nol: 0.1% phosphoric acid solution (50:50) at a flow rate of
1 ml/min with an injection volume of 10 μl. A sample
containing Rosmarinic acid was used as a control.
Cell culture
Human colon carcinoma HT-29 cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA,
USA). The cells were grown in DMEM containing 10%
(v/v) FBS, and 100 Units/ml penicillin and 100 μg/ml
streptomycin in a 37°C humidified incubator with 5%
CO2. The cells were subcultured at 80-90% confluency.
Animals
Male BALB/c athymic (nude) mice (with an initial body
weight of 20–22 g) were obtained from Shanghai SLACLaboratory Animal Co., Ltd. (Shanghai, China) and
housed under pathogen-free conditions with controlled
temperature (22°C), humidity, and a 12 hour light/dark
cycle. Food and water were given ad libitum throughout
the experiment. All animal treatments were performed
strictly in accordance with international ethical guide-
lines and the National Institutes of Health Guide
concerning the Care and Use of Laboratory Animals.
The experiments were approved by the Institutional
Animal Care and Use Committee of Fujian University of
Traditional Chinese Medicine.
In vivo tumor xenograft study
HT-29 cells were grown in culture and then detached by
trypsinization, washed, and resuspended in serum-free
DMEM. 1.5 × 106 of cells mixed with Matrigel (1:1) were
subcutaneously injected in the right flank area of
athymic nude mice to initiate tumor growth. After 3 days
of xenograft implantation, mice were randomized into
two groups (n = 9) and given intra-gastric administration
of 6 g/kg of EESP or saline daily, 5 days a week for
16 days. Body weight and tumor growth were measured
every two days. Tumor growth was determined by meas-
uring the major (L) and minor (W) diameter with a
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the following formula: tumor volume = π/6 × L ×W2. At
the end of experiment, the animals were anaesthetized
with pelltobarbitalum natricum, and the tumor tissue
was removed and weighed, and part of tumor was fixed
in buffered formalin and the remaining was stored at -80°C
for molecular analyses.
Evaluation of cell viability by MTT Assay
Cell viability was assessed by the 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) colorimet-
ric assay. HT-29 cells were seeded into 96-well plates at a
density of 1 × 104 cells/well in 0.1 ml medium. The cells
were treated with various concentrations of EESP for 24 h.
Treatment with 0.5% DMSO was included as vehicle con-
trol. At the end of the treatment, 10 μl MTT (5 mg/ml in
phosphate buffered saline, PBS) were added to each well,
and the samples were incubated for an additional 4 h at
37°C. The purple-blue MTT formazan precipitate was
dissolved in 100 μl DMSO. The absorbance was measured
at 570 nm using an ELISA reader (BioTek, Model
ELX800, USA).
Histological examination by HE staining
Tumor tissues were fixed with 10% buffered formalin
for 24 h. Samples were then paraffin-embedded, sec-
tioned, and stained with hematoxylin and eosin (H&E).
Histopathological changes were observed under a light
microscope.
RNA extraction and RT-PCR analysis
Briefly, Total RNA was isolated from fresh tumor with
Trizol reagent. Oligo(dT)-primed RNA (1 μg) was reverse
transcribed with SuperScript II reverse transcriptase
according to the manufacturer’s instructions. The obtained
cDNA was used to determine the mRNA amount of Bcl-2,
Bax, Cyclin D1, CDK4, VEGF-A and VEGFR2 by PCR
with Taq DNA polymerase (Fermentas). GAPDH was used
as an internal control. The primers used for amplification
of Bcl-2, Bax, Cyclin D1, CDK4, VEGF-A , VEGFR2, and
GAPDH transcripts are as follows: Bcl-2 forward 5′-CAG
CTG CAC CTG ACG CCC TT-3 and reverse 5′-GCC
TCC GTT ATC CTG GAT CC-3′; Bax forward 5′-TGC
TTC AGG GTT TCA TCC AGG-3′ and reverse 5′-TGG
CAA AGT AGA AAA GGG CGA-3′; Cyclin D1 forward
5′-TGG ATG CTG GAG GTC TGC GAG GAA-3′ and
reverse 5′-GGC TTC GAT CTG CTC CTG GCA GGC-
3′; CDK4 forward 5′-CAT GTA GAC CAG GAC CTA
AGC-3′ and reverse 5′-AAC TGG CGC ATC AGA TCC
TAG-3′; GAPDH forward 5′-GT CAT CCA TGA CAA
CTT TGG-3′ and reverse 5′-GA GCT TGA CAA AGT
GGT CGT-3′; VEGF-A forward 5- CAT CCT GGC CTC
GCT GTC −3 and reverse 5- CTC GCT CCA ACC GAC
TGC −3; VEGFR-2 forward 5- TGG CTC ACA GGCAAC ATC −3 and reverse 5- CTT CCT TCC TCA CCC
TTC −3.
In situ apoptosis detection by TUNEL
Briefly, sequential 4 μm tissue sections were adhered
to silane-coated slides and allowed to dry at room
temperature (RT). Subsequently, sections were depa-
raffinized and rehydrated. Protein digestion was done by
incubating tissue sections in 20 mg/ml proteinase K
(Worthington Co., Lakewood, USA) for 15 min at RT. En-
dogenous peroxidase was inactivated with 2% H2O2 in dis-
tilled water (dH2O) for 5 min, RT. The labeling mixture
containing biotinylated dUTP in TdT enzyme buffer was
added to sections and incubated at 37°C in a humified
chamber for 1 h. After stopping the enzymatic reaction,
sections were rinsed with PBS, covered with anti-
digoxigenin peroxidase conjugate and incubated for
30 min at RT in a humified chamber. Then, sections were
incubated in TBS with 0.05% diaminobenzidine (DAB)
plus 3% H2O2 until color development achieved. Finally,
sections were washed, counterstained in haematoxylin,
dehydrated, and mounted with DPX (Panreac SA,
Barcelona, Spain) and as a negative control active TdT
buffer was replaced by the kit equilibration buffer.
Immunohistochemostry
After fixed with 10% formaldehyde for 12 h, tumor sam-
ples were processed conventionally for paraffin-embedded
tumor slides. The slides were subjected to antigen retrieval
and the endogenous peroxidase activity was quenched
with hydrogen peroxide. After blocking non-specific pro-
teins with normal serum in PBS (0.1% Tween 20), slides
were incubated with rabbit polyclonal antibodies against
PCNA, CD31, pSTAT3, Bcl-2, Bax, CyclinD1, CDK4,
VEGF-A and VEGFR-2 (all in 1:200 dilution). After wash-
ing with PBS, slides were incubated with biotinylated sec-
ondary antibody followed by conjugated horseradish
peroxidase (HRP)-labelled streptavidin (Dako), and then
washed with PBS. The slides were then incubated with
diamino-benzidine (DAB, Sigma) as the chromogen,
followed by counterstaining with diluted Harris
hematoxylin (Sigma). After staining, five high-power fields
(400 ×) were randomly selected in each slide, and the aver-
age proportion of positive cells in each field were counted
using the true color multi-functional cell image analysis
management system (Image-Pro Plus, Media Cybernetics,
USA). To rule out any nonspecific staining, PBS was used
to replace the primary antibody as a negative control.
Statistical analysis
Data were presented as mean ± SD for the indicated num-
ber of independently performed experiments and the data
were analyzed using the SPSS package for Windows
(Version 11.5). Statistical analysis of the data was performed
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considered statistically significant.
Results
EESP inhibits the growth of colorectal cancer (CRC) in vivo
and in vitro
The anti-tumor activity of EESP in vivo was determined
through examination of the tumor weight and volume in
CRC xenograft mice; and its adverse effects were evaluated
by measuring the body weight changes. As shown in
Figure 2A & B, EESP treatment significantly reduced both
tumor volume and tumor weight, as compared to control
(P < 0.01). However, EESP treatment had no effect on the
changes of body weight (Figure 2C). Thus, it is suggested
that EESP effectively suppresses CRC growth in vivo, with-
out apparent signs of toxicity. To evaluate the in vitro
anti-tumor activity of EESP, we performed MTT assay to
examine its effect on the viability of human colon carcin-
oma HT-29 cells. As shown in Figure 2D, treatment with
0–2 mg/ml of EESP 24 h respectively reduced cell viability
by 22-63%, compared to untreated control cells (P < 0.01),
suggesting that EESP inhibits CRC cell growth in vitro in
dose-dependent manners.
EESP changes the histological structure of tumor in CRC
xenograft mice
The tumor histological changes in CRC mice were ob-
served via light microscopy after HE staining. As shown inFigure 2 Effect of EESP on tumor growth in colorectal cancer (CRC) xe
development, the mice were given intra-gastric administration of 6 g/kg/d
volume (A), tumor weight (B) and body weight (C) were was measured at
MTT assay after cells were treated with the indicated concentrations of EES
control cells (100%, treated with 0.5% DMSO vehicle). Data shown are aver
from three independent cell-based experiments. *P< 0.01, versus controls.Figure 3, tumor cells were densely packed in tissues of the
control group, but were sparse in tissues of EESP-treated
group. There was marked cytonuclear pleomorphism, mi-
totic activity (red arrow). Large blood vessels and red blood
cells could be observed in control group. In EESP group,
portions of cells were necrotic and inflammatory cells were
observed around the tumor tissue.
EESP induces apoptosis, inhibits cancer cell proliferation
and angiogenesis in CRC xenograft mice
Cell apoptosis and proliferation in tumors from CRC xeno-
graft mice was evaluated via immunohistochemical staining
(IHS) for TUNEL and PCNA, and the intratumoral
microvessel density (MVD) was examined by using IHS for
the endothelial cell-specific marker CD31. As shown in
Figure 4, the percentage of TUNEL-positive cells in EESP-
treated or control mice was 49.6 ± 6.63% or 34.5 ± 3.34%
(P < 0.01), respectively; whereas the proportion of cells ex-
pressing PCNA and CD31 was 12.49 ± 4.25% and 22.41 ±
4.11% in EESP-treated mice, 38.78 ± 5.09% and 35.34 ±
7.54% in controls. Collectively, these data suggest that
EESP promotes colorectal cancer cell apoptosis, as well as
inhibits cell proliferation and inhibits tumor angiogenisis.
EESP suppresses STAT3 phosphoralytion in CRC xenograft
mice
After activated via phosphorylation, STAT3 modulates
the expression of key genes involved in the regulation ofnograft mice and HT-29 colon cancer cells. After tumor
dose of EESP or saline daily, 5 days per week for 16 days. Tumor
the end of experiment. (D) HT-29 cell viability was determined by the
P for 24 h. The data were normalized to the viability or survival of
ages with S.D. (error bars) from 9 individual mice in each group or
Figure 3 Effect of EESP on the structural changes of tumor in CRC mice. Tumor tissues were fixed with 10% buffered formalin for 24 h.
Samples were then paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E). Histopathological changes were observed
under a light microscope. Images are representative photographs taken at a magnification of 200 ×.
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examined the effect of EESP on STAT3 phosphoralytion
level (pSTAT3) using IHS assay in tumor tissues. Data
from Figure 5 indicated that the percentage of pSTAT3-
positive cells in control or EESP-treated mice was 41.71 ±
6.59% and 18.24 ± 3.63%, respectively (P < 0.01),
suggesting that EESP treatment significantly suppresses
the activation of STAT3 pathway in CRC mice.Figure 4 Effect of EESP on cell apoptosis, proliferation and angiogeni
control and EESP-treated group were processed for immunohistochemical
images taken at a magnification of 400 ×. Quantification of immunohistoch
Data shown are averages with S.D. (error bars) from 9 individual mouse inEESP regulates the expression of Bcl-2, Bax, Cyclin D1,
CDK4, VEGF-A and VEGFR-2 in CRC xenograft mice
To further explore the mechanism of EESP’s anti-tumor
activity, we performed RT-PCR and IHS analyses to re-
spectively examine the mRNA and protein expression of
Bcl-2, Bax, Cyclin D1, CDK4, VEGF-A and VEGFR-2 in
CRC mice. PCR data showed that EESP treatment signifi-
cantly reduced the mRNA expression of pro-proliferativesis in CRC mice. At the end of the experiment, tumor tissues from
staining for TUNEL, PCNA or CD31. The photographs are representative
emical assay was represented as percentage of positively-stained cells.
each group. *P< 0.01, versus controls.
Figure 5 Effect of EESP on phosphorylation of STAT3 in CRC mice. At the end of the experiment, tumor tissues from control and
EESP-treated group were processed for immunohistochemical staining for phosphorylated STAT3 (pSTAT3) or total STAT3. The photographs are
representative images taken at a magnification of 400 ×. Quantification of immunohistochemical assay was represented as percentage of
positively-stained cells. Data shown are averages with S.D. (error bars) from 9 individual mouse in each group. *P< 0.01, versus controls.
Figure 6 Effect of EESP on the expression of Bcl-2, Bax, Cyclin D1, CDK4, VEGF-A and VEGFR-2 in CRC mice. (A) The mRNA levels in
tumor tissues from control and EESP-treated group were determined by RT-PCR. GAPDH was used as an internal control. The data of
densitometric analysis were normalized to the mean mRNA expression of untreated control (100%). (B-D) The protein expression of Bcl-2, Bax,
Cyclin D1, CDK4, VEGF-A and VEGFR-2 in tumor tissues was analyzed via immunohistochemical assay. The photographs are representative images
taken at a magnification of 400 ×. Quantification of immunohistochemical assay was represented as percentage of positively-stained cells. Data
shown are averages with S.D. (error bars) from 9 individual mouse in each group. *P< 0.01, versus controls.
Lin et al. BMC Complementary and Alternative Medicine 2013, 13:144 Page 7 of 10
http://www.biomedcentral.com/1472-6882/13/144
Lin et al. BMC Complementary and Alternative Medicine 2013, 13:144 Page 8 of 10
http://www.biomedcentral.com/1472-6882/13/144Cyclin D1 and CDK4, anti-apoptotic Bcl-2, pro-angiogenic
VEGF-A and VEGFR-2 in CRC mice, whereas that of pro-
apoptotic Bax was significantly increased after EESP treat-
ment (Figure 6A). In addition, results of IHS assay showed
that the protein expression patterns of these factors were
similar to their respective mRNA levels (Figure 6B-D).
The percentage of Bcl-2-, Bax-, Cyclin D1-, CDK4-,
VEGF-A- or VEGFR-2- positive cells in control group was
25.1 ± 3.09%, 19.6 ± 3.17%, 41.85 ± 8.29% , 55.14 ± 7.57%,
48.01 ± 6.54% or 29.17 ± 5.57%, respectively, whereas that
in EESP-treated mice was 12.37 ± 2.14%, 27.84 ± 4.13%,
15.71 ± 3.27%, 32.17 ± 4.3%, 26.14 ± 3.33% or 10.4 ± 2.54%
(P < 0.01).
Discussion
The development of cancer including colorectal cancer
(CRC) is strongly associated with the dysregulation of
multiple biological processes, such as imbalance between
cell apoptosis and proliferation, and uncontrolled angio-
genesis, which is mediated by aberrant activation of mul-
tiple intracellular signal transduction pathways. Given
the complexity of cancer pathogenesis and progression,
many of the currently used anti-tumor agents, which
typically target a single intracellular pathway, might not
always be effective on complex tumor systems but often
generates drug resistance after long-term use. Addition-
ally, most currently used chemotherapies possess intrin-
sic toxicity against normal cells. Thus, development of
novel anti-cancer agents is needed. Natural products,
such as traditional Chinese medicines (TCM), have been
used clinically for thousands of years as important alter-
native remedies for a wide variety of diseases including
cancer, without apparent adverse effects. Moreover,
TCM are considered to be multi-component and multi-
target agents exerting their therapeutic function in a
more holistic way [35-38]. Therefore, discovering natur-
ally occurring anti-tumor agents has received great inter-
est. Spica Prunellae is a well-known Chinese medicinal
herb with multiple pharmacological applications includ-
ing anti-tumor property. The anti-cancer activity of
Spica Prunellae was recorded in several ancient Chinese
medical books, including < Treasury of Words on the
Materia Medica > (‘Ben Cao Hui Yan’ in Chinese) written
in Ming Dynasty, and < A Newly Revised Materia
Medica > (‘Ben Cao Cong Xin’ in Chinese) written in
Qing Dynasty. Indeed, Spica Prunellae has long been used
as a major component in several TCM formulas for cancer
treatment [39,40]. Although we previously demonstrated
the anti-cancer activities of Spica Prunellae in vitro
[33,34], the therapeutic efficacy against tumor growth
in vivo and the underlying mechanism remain largely un-
clear. Using a CRC mouse xenograft model, in this study
we found that the ethanol effect of Spica Prunellae (EESP)
significantly reduced both tumor volume and tumorweight in CRC xenograft mice, whereas EESP treatment
had no effect on the changes of body weight, demonstrat-
ing that Spica Prunellae is potent in suppressing CRC
growth in vivo, without apparent signs of toxicity.
Cancer cell is characterized by imbalance between cell
apoptosis and proliferation [41]. Mitochondria play an im-
portant role in this process of apoptosis, which is highly
regulated by Bcl-2 family proteins including both anti-
apoptotic members such as Bcl-2 and pro-apoptotic
members such as Bax. The ratio of anti- and pro-
apoptotic Bcl-2 family members determines the fate of
cells, and alteration of the ratio by aberrant expression of
these proteins impairs the normal apoptotic program con-
tributing to various diseases including cancer. For in-
stance, higher Bcl-2 to Bax ratios are commonly found in
cancers, which not only confers a survival advantage to
the cancer cells but also causes resistance to chemother-
apies [42]. Eukaryotic cell proliferation is primarily regu-
lated by cell cycle, wherein G1/S transition is a major
checkpoint responsible for initiation and completion of
DNA replication. G1/S progression is strongly regulated
by the combined activity of the Cyclin D1/CDK4 complex
[43]. An unchecked or hyperactivated Cyclin D1/CDK4
complex often leads to uncontrolled cell division and
therefore cancers [44,45]. Therefore, re-balancing of cell
apoptosis and proliferation via regulation of the expression
of apoptosis- or cell cycle-related genes is a promising
strategy for cancer chemotherapies. Using a CRC mouse
xenograft model, we demonstrated that the ethanol effect
of Spica Prunellae (EESP) inhibited cancer growth in vivo,
without apparent toxicity. By using immunohistochemical
staining for TUNEL and PCNA we found that EESP pro-
moted apoptosis and inhibited proliferation in tumor tis-
sues. In addition, the pro-apoptotic and anti-proliferative
activities of EESP were mediated by its effects on the
expression of relevant genes. EESP treatment profoundly
increased the pro-apoptotic Bax/Bcl-2 ratio and down-
regulated the expression of pro-proliferative Cyclin D1
and CDK4.
Angiogenesis, a process involving the growth of new
blood vessels from the pre-existing vasculature, is essen-
tial for continued growth of the tumor and provides an
avenue for hematogenous metastasis [46]. Vascular
endothelial growth factor A (VEGF-A) is one of the
most effective biologic inducers of angiogenesis, which is
highly expressed in a wide variety of human cancers and
is associated with cancer progression, invasion and me-
tastasis, and poor patient prognosis. VEGF-A exerts its
pro-angiogenic function via binding to its specific recep-
tors including VEGFR-2 which is located on vascular
endothelial cells. Binding of VEGF-A to VEGFR-2 leads
to series of angiogenic processes [47]. Herein, we found
that EESP significantly reduced the intratumoral
microvessel density (MVD) in CRC xenograft mice via
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demonstrating its in vivo anti-angiogenic activity.
STAT3 is a crucial transcription factor that plays an
important role in relaying extracellular signals initiated by
cytokines and growth factors from the cytoplasm to the
nucleus. Following activation via phosphorylation,
STAT3 proteins dimerize and translocate to the nucleus
where they regulate the expression of numerous critical
genes involved in cell cycle progression, proliferation,
and angiogenesis, including above-mentioned Bcl-2,
Bax, Cyclin D1, CDK4 and VEGF-A. Therefore, sup-
pression of STAT3 activation should be a promising
approach in the development of anti-cancer therapies.
Using immunohistochemical staining here we observed
that EESP significantly reduced the phosphoralytion
level of STAT3 in tumors of CRC mice, consistent with
its pro-apoptotic, anti-proliferative and anti-angiogenic
activities.
Conclusions
In conclusion, for the first time we demonstrate that
Spica Prunellae inhibits colorectal cancer growth in vivo
via promoting the apoptosis of cancer cells, inhibition of
proliferation and anti- angiogenesis, which is mediated
by the suppression of the STAT3 pathway. Our findings
suggest that Spica Prunellae may be a potential novel
therapeutic agent for the treatment of cancers with con-
stitutive activation of STAT3.
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